A Phase 1/2 interventional study of 10 mg OPC-167832 and 30 mg OPC-167832 in Pulmonary TB, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 3 sites in South Africa. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2023-11-18.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing OPC-67683 in Tuberculosis, Pulmonary — 1 open to participants now, 4 under way, 2 of them phase 3. OPC-67683 · Tuberculosis, Pulmonary.
Among the 10 studies testing OPC-67683 in Tuberculosis, Pulmonary, this one is the 7th largest by enrollment, is the only one that started in 2018, and was the 4th registered.
319 studies on the registry are indexed under Tuberculosis, Pulmonary; 71 are open to participants now.
Browse Tuberculosis, Pulmonary studies →1 of the 10 studies testing OPC-67683 in Tuberculosis, Pulmonary is open now, in 5 countries. Recruiting first, the newest first:
University College, London · Sites in Moldova, South Africa, Tanzania and 2 more countries
Ages 18+
By country, each count listing its studies:
OPC-67683: first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 46 Tuberculosis, Pulmonary studies recruiting now, 22 (48%) set no upper age limit and 20 (43%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 7 · Phase 3 4
First in 2006; this study’s year is marked.
This study's enrollment of 122 is below the median of 146 across 227 interventional studies indexed under Tuberculosis, Pulmonary.
Median enrollment 208 across the 10 interventional studies. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 10 have an industry lead sponsor. The 8 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 4 studies filed under Tuberculosis, Pulmonary — fewer than ten, so there is no comparison to draw.
3 of the studies testing OPC-67683 in Tuberculosis, Pulmonary that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05766267Phase 3Centers for Disease Control and PreventionShort-course Regimens for the Treatment of Pulmonary Tuberculosis | 2026-12-31 |
| NCT06649721Phase 3Huashan HospitalInnovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort | 2027-02-28 |
| NCT06114628University College, LondonPlatform Assessing Regimens and Durations In a Global Multisite Consortium for TB | 2027-02-24 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies testing OPC-67683 in Tuberculosis, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This trial will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of multiple oral doses of OPC-167832 in participants with uncomplicated, smear-positive, drug-susceptible pulmonary tuberculosis (TB).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single dose of RHEZ (each tablet containing 150 milligrams (mg) rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), orally, once daily (QD) from Day 1 through Day 20.
Drug: RHEZ
Participants received OPC-167832, 10 mg, orally, QD, from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
Drug: 10 mg OPC-167832
Participants received OPC-167832, 30 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
Drug: 30 mg OPC-167832
Participants received OPC-167832, 90 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
Drug: 90 mg OPC-167832
Participants received OPC-167832, 3 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
Drug: 3 mg OPC-167832
Participants received OPC-167832, 30 mg, in combination with delamanid, 300 mg, orally, QD from Day 1 through Day 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
Drug: 30 mg OPC-167832 + 300 mg delamanid
Participants received OPC-167832, 30 mg, in combination with BDQ, orally, QD, from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. BDQ was then administered at a dose of 400 mg, QD, orally from Days 3 to 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
Drug: 30 mg OPC-167832 + 400 mg BDQ
Participants received OPC-167832, 30 mg, in combination with delamanid, 300 mg and BDQ, 400 mg, orally, QD, from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. BDQ was then administered at a dose of 400 mg, orally, QD from Days 3 to 14. After Day 14, participants received RHEZ according to the local standard of care regimen up to Day 20.
Drug: 30 mg OPC-167832 + 300 mg delamanid + 400 mg BDQ
Participants received a single dose of RHEZ (each tablet containing 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol), orally, QD, from Day 1 through Day 20.
Drug: RHEZ
Once daily oral dose of 10 mg OPC-167832 from Day 1 through Day 14.
Once daily oral dose of 30 mg OPC-167832 from Day 1 through Day 14.
Once daily oral dose of 90 mg OPC-167832 from Day 1 through Day 14.
Once daily oral dose of 3 mg OPC-167832 from Day 1 through Day 14.
RHEZ was used in both Stage 1 and Stage 2. Each tablet contains 150 mg rifampicin, 75 mg isoniazid, 400 mg pyrazinamide, and 275 mg ethambutol. Participants received a single-dose from Day 1 through Day 20. The total number of tablets per day was based on the pretreatment body weight: * Participants weighing 30 to 37 kg received 2 tablets per day * Participants weighing 38 to 54 kg received 3 tablets per day * Participants weighing 55 to 70 kg received 4 tablets per day * Participants weighing \> 70 kg received 5 tablets per day
Drug pages: Quabodepistat · OPC-67683
Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid from Day 1 through Day 14.
Once daily oral dose of 30 mg OPC-167832 plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
Once daily oral dose of 30 mg OPC-167832 plus 300 mg delamanid plus 400 mg BDQ from Day 1 through Day 14. Participants received a loading dose of 700 mg BDQ on Day 1 and 500 mg on Day 2. The dose of BDQ was 400 mg QD for Days 3 to 14.
Stage 1: Change From Baseline in TB Bacterial Load in Sputum as a Measure of Early Bactericidal Activity (EBA)
Bacterial load in sputum at each collection time point was measured by CFU counts on agar media culture. EBA was determined by the rate of decline per day in log10CFU/mL during the first 14 days of treatment. Change from baseline in log 10 CFU was calculated as post-baseline minus baseline. A larger EBA in positive direction indicates a better drug effect.
Time frame: Baseline to Day 14
Stage 1 and Stage 2: Maximum (Peak) Plasma Concentration (Cmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Stage 1 and Stage 2: Cmax at Steady-state (Cmax,ss) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 1 and Stage 2: Time to Cmax (Tmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Stage 1 and Stage 2: Tmax of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 1 and Stage 2: Area Under the Concentration-Time Curve (AUC) From Time Zero to Time t (the Last Observable Concentration, Here t=24) (AUC0-24), for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Stage 1 and Stage 2: AUC Calculated Over the Dosing Interval at Steady-state (AUCτ) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 1 and Stage 2: Terminal-phase Elimination Half-life (t1/2,z) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable from non-compartmental analysis (NCA). The values reported for this outcome measure (OM) are estimates and not actual observed data.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 1 and Stage 2: Apparent Clearance From Plasma at Steady-state (CLss/F) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 1 and Stage 2: Accumulation Ratio of Cmax (RCmax) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 1 and Stage 2: Accumulation Ratio of AUC (RAUC) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 1 and Stage 2: Cmax Normalized to Dose (Cmax/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: AUCτ Normalized to Dose (AUCτ/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2)
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: Cmax of Delamanid
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Stage 2: Cmax,ss of Delamanid
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: Tmax of Delamanid
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Stage 2: Tmax of Delamanid
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: AUC0-24 of Delamanid
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Stage 2: AUCτ of Delamanid
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: T1/2,z of Delamanid
T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: CLss/F of Delamanid From Plasma
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: RCmax of Delamanid
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: RAUC of Delamanid
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: Cmax/Dose of Delamanid
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: AUCτ/Dose of Delamanid
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: Cmax of Bedaquiline
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Stage 2: Cmax,ss of Bedaquiline
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: Tmax of Bedaquiline
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Stage 2: Tmax of Bedaquiline
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: AUC0-24 of Bedaquiline
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Stage 2: AUCτ of Bedaquiline
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: T1/2,z of Bedaquiline
T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data. Hence, the value might not lie within the sampling timepoints provided in the timeframe.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: CLss/F of BDQ From Plasma
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: Cmax/Dose of Bedaquiline
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: AUCτ/Dose of Bedaquiline
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 1 and Stage 2: Number of Participants With Treatment-emergent Adverse Events (AEs)
An AE is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were all AEs which started after the start of randomized study drug treatment or if the event was continuous from baseline and was serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy.
Time frame: From first dose of study drug to end of follow up period (up to 34 days)
Stage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Vital Sign Values
Time frame: From first dose of study drug to end of follow up period (up to 34 days)
Stage 1 and Stage 2: Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Parameters
Time frame: From first dose of study drug to end of follow up period (up to 34 days)
Stage 1 and Stage 2: Change From Baseline in Lipoarabinomannan (LAM) in the Mycobacteria Growth Indicator Tube® (MGIT) System
LAM is a key component of the M. tuberculosis cell wall and the decline of sputum LAM concentrations has been shown to correlate closely with CFU decreases in sputum counted on agar media during the first 14 days of TB treatment. Sputum LAM concentration at each collection time point was measured using MGIT system. Baseline LAM was calculated as the log 10 of the average from Day -2 and Day -1 and the change from baseline in log10 was calculated as post-baseline minus baseline for each parameter.
Time frame: Baseline to Day 14
Stage 1 and Stage 2: Change From Baseline in Time to Detection (TTD) in the MGIT System
TTD is the time from start of inoculation of a sputum sample until a MGIT machine detects a positive signal during the 42-day incubation period. One TTD measurement, reported in days and hours was taken at each of the visits at Days -2, -1, 2, 4, 6, 8, 10, 12 and 14. TTD values were then calculated as "days + hours/24" to be used in deriving the analysis values of TTD. Each sample collected from Day -2 to Day 14 were inoculated for 42 days. Baseline TTD was derived using Day -2 and Day -1 MGIT culture with a pure positive result for Mycobacterium tuberculosis. Postbaseline TTD analysis values from Day 1 were derived based on the MGIT culture result as follows: If MGIT culture result was negative for MTB complex, TTD was set to 42 days; If the MGIT culture was pure positive for MTB, but the TTD took longer than 42 days, TTD was capped at 42 days.
Time frame: Day 1 to Day 14 of treatment period + 42 days of inoculation period (up to 56 days)
Stage 2: Change From Baseline in TB Bacterial Load in Sputum as a Measure of EBA
Bacterial load in sputum at each collection time point was measured by CFU counts on agar media culture. EBA was determined by the rate of decline per day in log10CFU/mL during the first 14 days of treatment. Change from baseline in log 10 CFU was calculated as post-baseline minus baseline. A larger EBA in positive direction indicates a better drug effect.
Time frame: Baseline to Day 14
Stage 2: Plasma Concentration of Rifampin
Time frame: 2 hours and 6 hours post-dose on Day 14
Stage 1: Plasma Concentration of Isoniazid
Time frame: 2 hours and 6 hours post-dose on Day 14
Stage 2: Cmax of DM-6705
DM-6705 is a metabolite of delamanid.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Stage 2: Cmax,ss of DM-6705
DM-6705 is a metabolite of delamanid.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: Tmax of DM-6705
DM-6705 is a metabolite of delamanid.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: AUC0-24 for DM-6705
DM-6705 is a metabolite of delamanid.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: T1/2,z of DM-6705
T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) was determined in the terminal phase after drug administration, which was calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data. Hence, the value might not lie within the sampling timepoints provided in the timeframe.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: Cmax of N-Desmethyl Bedaquiline
N-Desmethyl Bedaquiline is a metabolite of BDQ.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1
Stage 2: Cmax,ss of N-Desmethyl Bedaquiline
N-Desmethyl Bedaquiline is a metabolite of BDQ.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: Tmax of N-Desmethyl Bedaquiline
N-Desmethyl Bedaquiline is a metabolite of BDQ.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours (±15 minutes) postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: AUC0-24 for N-Desmethyl Bedaquiline
N-Desmethyl Bedaquiline is a metabolite of BDQ.
Time frame: Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, and 24 hours postdose on Day 1; Predose and 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 72, 96, 120 and 144 hours postdose on Day 14
Stage 2: Number of Participants With TEAEs on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline
An AE is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were all adverse events which started after the start of randomized study drug treatment or if the event was continuous from baseline and was serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy.
Time frame: From first dose of study drug to end of follow up period (up to 34 days)
Stage 2: Number of Participants With Clinically Significant Vital Sign Changes on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline
Time frame: From first dose of study drug to end of follow up period (up to 34 days)
Stage 2: Number of Participants With Clinically Significant Changes in ECG Evaluations on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline
Time frame: From first dose of study drug to end of follow up period (up to 34 days)
Correlation of QT Interval and Plasma Concentrations of OPC-167832 and/or Delamanid and/or Bedaquiline
Time frame: Day 1 and Day 14
Participants took part in this study at two investigative sites in South Africa from 18 October 2018 to 11 March 2022.
| Milestone | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ | Stage 2: RHEZ |
|---|---|---|---|---|---|---|---|---|---|
| Started | 14 | 14 | 17 | 14 | 17 | 14 | 14 | 14 | 4 |
| Efficacy analysis set/ mitt set | 14 | 11 | 14 | 14 | 15 | 11 | 11 | 12 | 4 |
| Safety analysis set | 14 | 14 | 17 | 14 | 16 | 13 | 13 | 14 | 4 |
| Pharmacokinetic (pk) analysis set | 14 | 14 | 17 | 14 | 11 | 13 | 13 | 14 | 4 |
| Completed | 14 | 14 | 14 | 13 | 16 | 10 | 9 | 11 | 4 |
| Not completed | 0 | 0 | 3 | 1 | 1 | 4 | 5 | 3 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 3 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Non-covid related adverse event | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 0 |
| Withdrew: Covid related adverse event | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 1 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 |
Bacterial load in sputum at each collection time point was measured by CFU counts on agar media culture. EBA was determined by the rate of decline per day in log10CFU/mL during the first 14 days of treatment. Change from baseline in log 10 CFU was calculated as post-baseline minus baseline. A larger EBA in positive direction indicates a better drug effect.
| sputum log10CFU/mL | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ |
|---|---|---|---|---|---|
| Stage 1: Change From Baseline in TB Bacterial Load in Sputum as a Measure of Early Bactericidal Activity (EBA) | -1.93 ± 0.98 | -2.12 ± 1.01 | -2.08 ± 0.75 | -1.69 ± 1.15 | -2.79 ± 0.96 |
| nanogram per milliliter (ng/mL) | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Maximum (Peak) Plasma Concentration (Cmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 20.7 ± 6.92 | 53.7 ± 9.16 | 128 ± 50.5 | 391 ± 116 | 157 ± 44.1 | 154 ± 39.6 | 140 ± 41.2 |
| ng/mL | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Cmax at Steady-state (Cmax,ss) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 28.2 ± 10.9 | 67.3 ± 11.9 | 190 ± 63.6 | 492 ± 99.8 | 208 ± 60.5 | 175 ± 31.3 | 183 ± 51.9 |
| hours | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Time to Cmax (Tmax) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 3.17 (2.17 to 4.17) | 4.15 (1.17 to 5.15) | 3.15 (2.15 to 5.17) | 3.25 (2.13 to 5.17) | 2.83 (1.83 to 4.83) | 3.17 (1.17 to 5.18) | 3.83 (1.80 to 7.90) |
| hours | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Tmax of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 3.17 (1.18 to 5.17) | 3.15 (1.15 to 5.13) | 3.13 (2.13 to 5.13) | 3.17 (2.13 to 5.13) | 2.83 (1.82 to 5.83) | 3.13 (2.17 to 4.25) | 2.83 (1.83 to 4.85) |
| nanogram.hour per milliliter (ng*h/mL) | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Area Under the Concentration-Time Curve (AUC) From Time Zero to Time t (the Last Observable Concentration, Here t=24) (AUC0-24), for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 178 ± 65.1 | 569 ± 102 | 1290 ± 532 | 4050 ± 1240 | 1450 ± 392 | 1490 ± 490 | 1420 ± 378 |
| ng*h/mL | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: AUC Calculated Over the Dosing Interval at Steady-state (AUCτ) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 349 ± 143 | 874 ± 127 | 2490 ± 928 | 5690 ± 1010 | 2500 ± 709 | 2020 ± 563 | 2000 ± 730 |
T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable from non-compartmental analysis (NCA). The values reported for this outcome measure (OM) are estimates and not actual observed data.
| hours | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Terminal-phase Elimination Half-life (t1/2,z) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 22.3 (10.3 to 36.7) | 15.3 (9.2 to 22.5) | 14.2 (5.6 to 29.1) | 14.4 (9.8 to 30.1) | 14.4 (13.3 to 20.4) | 14.7 (6.2 to 22.1) | 11.2 (6.8 to 19.1) |
| mL/minute (min) | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Apparent Clearance From Plasma at Steady-state (CLss/F) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 164 ± 62.6 | 195 ± 28.8 | 231 ± 91.8 | 272 ± 53.8 | 215 ± 61.0 | 269 ± 88.5 | 283 ± 103 |
| ratio | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Accumulation Ratio of Cmax (RCmax) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 1.39 ± 0.381 | 1.26 ± 0.167 | 1.56 ± 0.399 | 1.36 ± 0.362 | 1.34 ± 0.349 | 1.23 ± 0.191 | 1.30 ± 0.244 |
| ratio | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Accumulation Ratio of AUC (RAUC) for OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 1.99 ± 0.550 | 1.60 ± 0.289 | 2.01 ± 0.565 | 1.55 ± 0.416 | 1.70 ± 0.378 | 1.47 ± 0.314 | 1.36 ± 0.237 |
| (ng/mL)/mg | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Cmax Normalized to Dose (Cmax/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 9.42 ± 3.63 | 6.73 ± 1.19 | 6.34 ± 2.12 | 5.46 ± 1.11 | 6.94 ± 2.02 | 5.85 ± 1.04 | 6.10 ± 1.73 |
| (ng*h/mL)/mg | Stage 1: 3 mg OPC-167832 | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|
| Stage 2: AUCτ Normalized to Dose (AUCτ/Dose) of OPC-167832 When Administered Alone (Stage 1) and in Combination With Delamanid, and BDQ (Stage 2) | 116 ± 47.6 | 87.4 ± 12.7 | 82.8 ± 30.9 | 63.3 ± 11.2 | 83.5 ± 23.6 | 67.2 ± 18.8 | 66.5 ± 24.3 |
| ng/mL | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Cmax of Delamanid | 181 ± 41.8 | 198 ± 57.5 |
| ng/mL | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Cmax,ss of Delamanid | 401 ± 102 | 442 ± 188 |
| hours | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Tmax of Delamanid | 3.82 (1.83 to 5.83) | 4.82 (2.83 to 7.90) |
| hours | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Tmax of Delamanid | 3.83 (1.83 to 5.83) | 3.83 (2.70 to 7.83) |
| ng.h/mL | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: AUC0-24 of Delamanid | 2140 ± 613 | 2440 ± 957 |
| ng*h/mL | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: AUCτ of Delamanid | 5460 ± 1620 | 5860 ± 2310 |
T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data.
| hours | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: T1/2,z of Delamanid | 25.4 (16.3 to 38.4) | 25.1 (17.6 to 56.4) |
| mL/min | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: CLss/F of Delamanid From Plasma | 983 ± 264 | 966 ± 330 |
| ratio | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: RCmax of Delamanid | 2.26 ± 0.647 | 2.19 ± 0.601 |
| ratio | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: RAUC of Delamanid | 2.69 ± 0.683 | 2.49 ± 0.897 |
| (ng/mL)/mg | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Cmax/Dose of Delamanid | 1.34 ± 0.339 | 1.47 ± 0.625 |
| (ng*h/mL)/mg | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: AUCτ/Dose of Delamanid | 18.2 ± 5.40 | 19.5 ± 7.71 |
| ng/mL | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Cmax of Bedaquiline | 5150 ± 1860 | 5750 ± 2320 |
| ng/mL | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Cmax,ss of Bedaquiline | 5030 ± 1850 | 6080 ± 1660 |
| hours | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Tmax of Bedaquiline | 5.17 (4.13 to 8.15) | 4.83 (3.82 to 7.90) |
| hours | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Tmax of Bedaquiline | 5.17 (3.15 to 5.20) | 4.85 (4.83 to 5.82) |
| ng*h/mL | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: AUC0-24 of Bedaquiline | 44900 ± 12800 | 47000 ± 15600 |
| ng*h/mL | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: AUCτ of Bedaquiline | 55900 ± 16000 | 66000 ± 19200 |
T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) is determined in the terminal phase after drug administration, which is calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data. Hence, the value might not lie within the sampling timepoints provided in the timeframe.
| hours | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: T1/2,z of Bedaquiline | NA (14.4 to 139.7) | 81.1 (54.2 to 155.4) |
| mL/min | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: CLss/F of BDQ From Plasma | 140 ± 85.9 | 109 ± 31.4 |
| (ng/mL)/mg | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Cmax/Dose of Bedaquiline | 12.6 ± 4.62 | 15.2 ± 4.14 |
| (ng*h/mL)/mg | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: AUCτ/Dose of Bedaquiline | 140 ± 40.0 | 165 ± 48.0 |
An AE is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were all AEs which started after the start of randomized study drug treatment or if the event was continuous from baseline and was serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy.
| Participants | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ | Stage 2: RHEZ |
|---|---|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Number of Participants With Treatment-emergent Adverse Events (AEs) | 10 | 13 | 13 | 11 | 15 | 9 | 11 | 9 | 3 |
| Participants | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ | Stage 2: RHEZ |
|---|---|---|---|---|---|---|---|---|---|
| Heart Rate: > 120 beats per minute (bpm) and >= 15 bpm Change from Baseline | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Diastolic Blood Pressure: < 50 mmHg and >= 15 mmHg Decrease from Baseline | 0 | 1 | 2 | 1 | 0 | 0 | 2 | 0 | 0 |
| Systolic Blood Pressure: < 90 mmHg and >= 20 mmHg Decrease from Baseline | 1 | 3 | 2 | 2 | 0 | 1 | 1 | 1 | 0 |
| Weight: >= 5% Increase from Baseline | 3 | 4 | 2 | 1 | 9 | 0 | 5 | 2 | 2 |
| Participants | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ | Stage 2: RHEZ |
|---|---|---|---|---|---|---|---|---|---|
| Rhythm: Ventricular Premature Beat | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| ST/T Morphology: Myocardial Ischemia | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| ST/T Morphology: Symmetrical T-wave Inversion | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
LAM is a key component of the M. tuberculosis cell wall and the decline of sputum LAM concentrations has been shown to correlate closely with CFU decreases in sputum counted on agar media during the first 14 days of TB treatment. Sputum LAM concentration at each collection time point was measured using MGIT system. Baseline LAM was calculated as the log 10 of the average from Day -2 and Day -1 and the change from baseline in log10 was calculated as post-baseline minus baseline for each parameter.
| log10 LAM picograms (pg)/ml | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|---|
| Raw | -1.52 ± 0.79 | -1.41 ± 0.75 | -1.44 ± 0.67 | -1.35 ± 0.76 | -1.19 ± 0.75 | -1.93 ± 1.22 | -0.97 ± 0.62 | -2.06 ± 1.03 |
| Processed | -1.43 ± 1.07 | -1.55 ± 0.90 | -1.40 ± 0.77 | -1.42 ± 0.74 | -1.05 ± 0.61 | -2.05 ± 1.26 | -0.87 ± 0.66 | -1.84 ± 1.39 |
TTD is the time from start of inoculation of a sputum sample until a MGIT machine detects a positive signal during the 42-day incubation period. One TTD measurement, reported in days and hours was taken at each of the visits at Days -2, -1, 2, 4, 6, 8, 10, 12 and 14. TTD values were then calculated as "days + hours/24" to be used in deriving the analysis values of TTD. Each sample collected from Day -2 to Day 14 were inoculated for 42 days. Baseline TTD was derived using Day -2 and Day -1 MGIT culture with a pure positive result for Mycobacterium tuberculosis. Postbaseline TTD analysis values from Day 1 were derived based on the MGIT culture result as follows: If MGIT culture result was negative for MTB complex, TTD was set to 42 days; If the MGIT culture was pure positive for MTB, but the TTD took longer than 42 days, TTD was capped at 42 days.
| days | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|---|---|---|---|---|
| Stage 1 and Stage 2: Change From Baseline in Time to Detection (TTD) in the MGIT System | 4.28 ± 2.88 | 9.54 ± 13.63 | 18.15 ± 15.06 | 3.33 ± 2.74 | 7.44 ± 1.65 | 8.93 ± 10.31 | 5.33 ± 2.54 | 14.26 ± 13.57 |
Bacterial load in sputum at each collection time point was measured by CFU counts on agar media culture. EBA was determined by the rate of decline per day in log10CFU/mL during the first 14 days of treatment. Change from baseline in log 10 CFU was calculated as post-baseline minus baseline. A larger EBA in positive direction indicates a better drug effect.
| Sputum log10 CFU/mL | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|
| Stage 2: Change From Baseline in TB Bacterial Load in Sputum as a Measure of EBA | -2.17 ± 1.83 | -1.97 ± 1.29 | -2.73 ± 1.51 |
| ng/mL | Stage 2: RHEZ |
|---|---|
| 2 hours Post-dose | 4020 ± 2450 |
| 6 hours Post-dose | 1880 ± 811 |
| microgram per millilitre (ug/mL) | Stage 1: RHEZ |
|---|---|
| 2 hours Post-dose | 4.16 ± 1.45 |
| 6 hours Post-dose | 1.58 ± 0.837 |
DM-6705 is a metabolite of delamanid.
| ng/mL | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Cmax of DM-6705 | 10.3 ± 10.5 | 14.6 ± 11.6 |
DM-6705 is a metabolite of delamanid.
| ng/mL | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Cmax,ss of DM-6705 | 84.0 ± 27.5 | 112 ± 51.9 |
DM-6705 is a metabolite of delamanid.
| hours | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Day 1 | 4.82 (1.83 to 23.63) | 4.83 (1.83 to 23.58) |
| Day 14 | 4.83 (0.33 to 7.83) | 4.85 (2.70 to 11.85) |
DM-6705 is a metabolite of delamanid.
| ng*h/mL | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Day 1 | 103 ± 54.2 | 166 ± 124 |
| Day 14 | 1620 ± 458 | 1980 ± 850 |
T1/2,z is the time required to divide the plasma concentration by two after reaching pseudo-equilibrium, and not the time required to eliminate half the administered dose. Half-life (T1/2) was determined in the terminal phase after drug administration, which was calculated from the relationship T1/2 = ln2/λz where λz is the terminal-phase slope obtainable using the NCA method. The values reported for this OM are estimates and not actual observed data. Hence, the value might not lie within the sampling timepoints provided in the timeframe.
| hours | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: T1/2,z of DM-6705 | NA (90.2 to 509.1) | NA (95.8 to 1219.9) |
N-Desmethyl Bedaquiline is a metabolite of BDQ.
| ng/mL | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Cmax of N-Desmethyl Bedaquiline | 95.4 ± 44.7 | 88.2 ± 17.5 |
N-Desmethyl Bedaquiline is a metabolite of BDQ.
| ng/mL | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Stage 2: Cmax,ss of N-Desmethyl Bedaquiline | 489 ± 154 | 575 ± 112 |
N-Desmethyl Bedaquiline is a metabolite of BDQ.
| hours | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Day 1 | 23.93 (6.17 to 24.05) | 11.86 (7.82 to 23.88) |
| Day 14 | 15.08 (0.00 to 48.0) | 7.83 (3.83 to 23.63) |
N-Desmethyl Bedaquiline is a metabolite of BDQ.
| ng*h/mL | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|
| Day 1 | 1380 ± 731 | 1410 ± 326 |
| Day 14 | 10100 ± 3080 | 11800 ± 1920 |
An AE is defined as any untoward medical occurrence in a clinical trial participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. TEAEs were all adverse events which started after the start of randomized study drug treatment or if the event was continuous from baseline and was serious, study drug-related, or resulted in death, discontinuation, interruption, or reduction of study therapy.
| Participants | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|
| Stage 2: Number of Participants With TEAEs on Administration of OPC-167832 in Combination With Delamanid and/or Bedaquiline | 9 | 11 | 9 |
| Participants | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|
| Heart Rate: > 120 bpm and >= 15 bpm change from baseline | 0 | 1 | 0 |
| Diastolic blood pressure: < 50 mmHg and >= 15 mmHg decrease from baseline | 0 | 2 | 0 |
| Systolic blood pressure: < 90 mmHg and >= 20 mmHg decrease from baseline | 1 | 1 | 1 |
| Weight: >= 5% increase from baseline | 0 | 5 | 2 |
| Participants | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ |
|---|---|---|---|
| Rhythm: Ventricular Premature Beat | 0 | 0 | 0 |
| ST/T Morphology: Myocardial Ischemia | 0 | 0 | 0 |
| ST/T Morphology: Symmetrical T-wave Inversion | 0 | 0 | 0 |
Results for this outcome have not been posted.
Collected over From first dose of study drug to end of follow up period (up to approximately 34 days in each Stage 1 and Stage 2). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1: 10 mg OPC-167832 | 0/14 (0%) | 0/14 (0%) | 10/14 (71.4%) |
| Stage 1: 30 mg OPC-167832 | 0/14 (0%) | 0/14 (0%) | 13/14 (92.9%) |
| Stage 1: 90 mg OPC-167832 | 0/17 (0%) | 0/17 (0%) | 13/17 (76.5%) |
| Stage 1: 3 mg OPC-167832 | 0/14 (0%) | 1/14 (7.1%) | 10/14 (71.4%) |
| Stage 1: RHEZ | 0/16 (0%) | 0/16 (0%) | 15/16 (93.8%) |
| Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | 0/13 (0%) | 0/13 (0%) | 9/13 (69.2%) |
| Stage 2: 30 mg OPC-167832 + 400 mg BDQ | 0/13 (0%) | 2/13 (15.4%) | 11/13 (84.6%) |
| Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ | 0/14 (0%) | 0/14 (0%) | 9/14 (64.3%) |
| Stage 2: RHEZ | 0/4 (0%) | 0/4 (0%) | 3/4 (75%) |
| Event | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ | Stage 2: RHEZ |
|---|---|---|---|---|---|---|---|---|---|
| Anal abscessInfections and infestations | 0/14 | 0/14 | 0/17 | 0/14 | 0/16 | 0/13 | 1/13 | 0/14 | 0/4 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/14 | 0/14 | 0/17 | 0/14 | 0/16 | 0/13 | 1/13 | 0/14 | 0/4 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 0/14 | 0/14 | 0/17 | 1/14 | 0/16 | 0/13 | 0/13 | 0/14 | 0/4 |
| Event | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ | Stage 2: RHEZ |
|---|---|---|---|---|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 1/14 | 5/14 | 3/17 | 2/14 | 6/16 | 0/13 | 1/13 | 2/14 | 1/4 |
| HeadacheNervous system disorders | 3/14 | 4/14 | 2/17 | 3/14 | 2/16 | 2/13 | 4/13 | 1/14 | 0/4 |
| NauseaGastrointestinal disorders | 1/14 | 0/14 | 0/17 | 1/14 | 1/16 | 2/13 | 0/13 | 3/14 | 1/4 |
| RashSkin and subcutaneous tissue disorders | 0/14 | 1/14 | 0/17 | 0/14 | 1/16 | 1/13 | 1/13 | 0/14 | 1/4 |
| HyperuricaemiaMetabolism and nutrition disorders | 0/14 | 0/14 | 0/17 | 0/14 | 0/16 | 0/13 | 0/13 | 0/14 | 1/4 |
| DizzinessNervous system disorders | 1/14 | 1/14 | 0/17 | 1/14 | 1/16 | 0/13 | 3/13 | 1/14 | 0/4 |
| Eye PainEye disorders | 0/14 | 3/14 | 0/17 | 0/14 | 0/16 | 0/13 | 0/13 | 0/14 | 0/4 |
| VomitingGastrointestinal disorders | 2/14 | 2/14 | 0/17 | 0/14 | 2/16 | 1/13 | 0/13 | 3/14 | 0/4 |
| Non-cardiac Chest PainGeneral disorders | 3/14 | 0/14 | 0/17 | 0/14 | 0/16 | 0/13 | 0/13 | 0/14 | 0/4 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/14 | 1/14 | 1/17 | 0/14 | 3/16 | 1/13 | 0/13 | 0/14 | 0/4 |
Randomized Analysis Set included participants who were randomized into the trial.
| Age, Continuous(years) | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ | Stage 2: RHEZ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 31.7 ± 14.6 | 34.9 ± 12.8 | 36.2 ± 13.3 | 37.2 ± 15.6 | 33.4 ± 10.9 | 34.1 ± 9.9 | 29.8 ± 8.9 | 30.1 ± 8.2 | 31.3 ± 9.5 | 33.4 ± 11.9 |
| Sex: Female, Male(Participants) | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ | Stage 2: RHEZ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 8 | 8 | 4 | 5 | 2 | 2 | 4 | 1 | 38 |
| Male | 10 | 6 | 9 | 10 | 12 | 12 | 12 | 10 | 3 | 84 |
| Ethnicity (NIH/OMB)(Participants) | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ | Stage 2: RHEZ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 14 | 12 | 17 | 14 | 15 | 14 | 14 | 14 | 4 | 118 |
| Unknown or Not Reported | 0 | 2 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 4 |
| Race/Ethnicity, Customized(Participants) | Stage 1: 10 mg OPC-167832 | Stage 1: 30 mg OPC-167832 | Stage 1: 90 mg OPC-167832 | Stage 1: 3 mg OPC-167832 | Stage 1: RHEZ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid | Stage 2: 30 mg OPC-167832 + 400 mg BDQ | Stage 2: 30 mg OPC-167832 + 300 mg Delamanid + 400 mg BDQ | Stage 2: RHEZ | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Black or African American | 8 | 7 | 11 | 6 | 8 | 7 | 10 | 9 | 3 | 69 |
| Other | 6 | 7 | 5 | 8 | 9 | 7 | 4 | 5 | 1 | 52 |
| White | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2018 to primary completion in Feb 2022, 39 months.
Results were first posted in Nov 2023, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Quabodepistat · OPC-67683
Otsuka Pharmaceutical Development & Commercialization, Inc. →